Analysis reveals 1-year progression-free survival of 41% in patients after CAR-T therapy failure, suggesting CPIs may improve outcomes.
Key Points
Forty-one percent of patients achieved a complete response after salvage treatment post-CAR-T failure, indicating a potential effective pathway.
Of those receiving treatment, 63.6% with checkpoint inhibitors had a significant 1-year progression-free survival compared to others, highlighting efficacy.
A retrospective examination of patients post-CAR-T therapy identified key characteristics of disease progression and treatment outcomes.
Findings emphasize the need for a structured management approach for young patients with primary mediastinal B-cell lymphoma post-CAR-T failure.